OneTest™ Premium can help with early detection of lung, liver, pancreas, and other cancers that are not widely screened for in the United States.
Previously, multi-cancer blood tests to screen for common types of cancer was only available in other countries. In the US, cancer screening has been normally limited to colon, breast, cervical (for women), and prostate (for men). OneTest™ Premium is now available in the US to screen for multiple types of cancers with a single blood test for common cancers including lung, liver, pancreatic, ovarian, prostate, kidney and others.
Advantages of OneTest™ Premium vs Other Multi-Cancer Tests
In internal validation studies of real world data, OneTest™ Premium has been shown to offer 27% better sensitivity for
stage 1 (early stage) cancer compared to the leading multi-cancer test that utilizes circulating cell free DNA. Click here to see study results
We measure tumor antigens (not genes) which can help detect cancer now, not in the future
Many popular DNA testing companies today offer not only ancestry analysis, but also tests for inherited genetic abnormalities that pre-dispose the consumer to various diseases. Such tests have very limited value for early cancer detection since recent studies have confirmed that fewer than 5% of the genetic mutations that cause cancer are inherited. Instead, most cancer-causing mutations result from random DNA copying errors over time.
OneTest™ Premium is powered and validated by real-world data from asymptomatic individuals
Most biomarker-based cancer tests are developed and validated using stored laboratory blood samples from cancer patients. The purported accuracy of these tests usually drops considerably when they are later used in a real-world screening setting (i.e. Individuals without signs or symptoms of cancer).